(Q39288216)

10 September 2017

title

Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund (English)

1 reference

10 September 2017

Ramya Ramaswami

1

1 reference

10 September 2017

Sean M O'Cathail

2

1 reference

10 September 2017

James H Brindley

3

1 reference

10 September 2017

Paul Silcocks

4

1 reference

10 September 2017

Sarah Mahmoud

5

1 reference

10 September 2017

Carlo Palmieri

6

1 reference

10 September 2017

language of work or name

English

0 references

publication date

24 December 2013

1 reference

10 September 2017

1 reference

10 September 2017

volume

10

1 reference

10 September 2017

issue

3

1 reference

10 September 2017

page(s)

363-376

1 reference

Structure-activity relationships of halichondrin B analogues: modifications at C.30-C.38.

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Eribulin mesylate in patients with refractory cancers: a Phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Rechallenging with anthracyclines and taxanes in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Transection of the oesophagus for bleeding oesophageal varices

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Okadaic acid, a cytotoxic polyether from two marine sponges of the genus Halichondria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.210

Halichondrins - antitumor polyether macrolides from a marine sponge

21 January 2018

1 reference

20 August 2023

https://opencitations.net/index/coci/api/v1/citations/10.1351/PAC198658050701

Identifiers

DOI

10.2217/FON.13.210

1 reference

10 September 2017

1 reference